

(70307)

Medical Benefit		Effective Date: 07/01/14	Next Review Date: 03/19
Preauthorization	Yes	Review Dates: 09/09, 09/10, 09/11, 07/12, 03/13, 03/14, 03/15, 03/16, 03/17, 03/18	

Preauthorization is required and must be obtained through Case Management.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: • With end-stage pulmonary disease	Interventions of interest are: • Lung transplant	Comparators of interest are: • Medical management	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity
Individuals: • With end-stage pulmonary disease	Interventions of interest are: • Lobar lung transplant	Comparators of interest are: • Medical management	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity
Individuals: • With a prior lung or lobar transplant who meet criteria for a lung transplant	Interventions of interest are: • Lung or lobar retransplant	Comparators of interest are: • Medical management	Relevant outcomes include: • Overall survival • Change in disease status • Treatment-related mortality • Treatment-related morbidity

Description

A lung transplant consists of replacing all or part of diseased lungs with healthy lung(s) or lobes. Transplantation is an option for patients with end-stage lung disease.

Summary of Evidence

For individuals who have end-stage pulmonary disease who receive lung transplantation, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. International registry data on a large number of patients receiving lung transplantation (> 50,000) found relatively high patient survival rates, especially among patients who survived the first year posttransplant. After adjusting for potential confounding factors, survival did not differ significantly after single- or double-lung transplant. Lung transplantation may be the only option for some patients with end-stage lung disease. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have end-stage pulmonary disease who receive lobar lung transplantation, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, change in disease status, and treatment-related mortality and morbidity. There are less data on lung lobar transplants than on whole-lung transplants, but several case series have reported reasonably similar survival outcomes between the procedures, and lung lobar transplants may be the only option for patients unable to wait for a whole-lung transplant. A 2017 systematic review found one-year survival rates in the available published studies ranging from 50% to 100%. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a prior lung or lobar transplant who meet criteria for a lung transplant who receive a lung or lobar lung retransplant, the evidence includes case series and registry studies. Relevant outcomes are overall survival, change in disease status, treatment-related mortality and morbidity. Data from registries and case series have found favorable outcomes with lung retransplantation in patients who meet criteria for initial lung transplantation. Given the exceedingly poor survival without retransplantation of patients who have exhausted other treatments, evidence of a moderate level of posttransplant survival is sufficient in this patient population. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy

Lung transplantation may be considered **medically necessary** for carefully selected patients with irreversible, progressively disabling, end-stage pulmonary disease unresponsive to maximum medical therapy (see Policy Guidelines).

A lobar lung transplant from a living or deceased donor may be considered **medically necessary** for carefully selected patients with end-stage pulmonary disease (see Policy Guidelines).

Lung or lobar lung retransplantation after a failed lung or lobar lung transplant may be considered **medically necessary** in patients who meet criteria for lung transplantation.

Lung or lobar lung transplantation is considered **investigational** in all other situations.

Policy Guidelines

Individual transplant facilities may have their own additional requirements or protocols that must be met in order for the patient to be eligible for a transplant at their facility.

Contraindications

Potential contraindications for lung transplant subject to the judgment of the transplant center include the following:

1. Known current malignancy, including metastatic cancer
2. Recent malignancy with high risk of recurrence
3. Untreated systemic infection making immunosuppression unsafe, including chronic infection
4. Other irreversible end-stage disease not attributed to lung disease
5. History of cancer with a moderate risk of recurrence
6. Systemic disease that could be exacerbated by immunosuppression
7. Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.

Policy-specific

8. Coronary artery disease not amenable to percutaneous intervention or bypass grafting, or associated with significant impairment of left ventricular function*; or
9. Colonization with highly resistant or highly virulent bacteria, fungi, or mycobacteria.

*Some patients may be candidates for combined heart-lung transplantation. See The Heart/Lung Transplant Protocol.

Patients must meet United Network for Organ Sharing guidelines for lung allocation score (LAS) greater than zero.

Lung-Specific Guidelines

Bilateral lung transplantation is typically required when chronic lung infection and disease is present (i.e., associated with cystic fibrosis and bronchiectasis). Some, but not all, cases of pulmonary hypertension will require bilateral lung transplantation.

Bronchiolitis obliterans is associated with chronic lung transplant rejection, and thus may be the etiology of a request for lung retransplantation.

Conditions for Etiologies of End-Stage Lung Disease

Bilateral bronchiectasis

Alpha-1 antitrypsin deficiency

Primary pulmonary hypertension

Cystic fibrosis (both lungs to be transplanted)

Bronchopulmonary dysplasia

Postinflammatory pulmonary fibrosis

Idiopathic or interstitial pulmonary fibrosis

Sarcoidosis

Scleroderma

Lymphangiomyomatosis

Emphysema

Eosinophilic granuloma

Bronchiolitis obliterans

Recurrent pulmonary embolism

Pulmonary hypertension due to cardiac disease

Chronic obstructive pulmonary disease

Eisenmenger syndrome

Medicare Advantage

If a transplant is needed, we arrange to have the Medicare–approved transplant center review and decide whether the patient is an appropriate candidate for the transplant.

Background*End-Stage Lung Disease*

End-stage lung disease may be the consequence of a number of different etiologies. The most common indications for lung transplantation are chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, α_1 -antitrypsin deficiency, and idiopathic pulmonary arterial hypertension.

Treatment

Before consideration for transplant, patients should be receiving maximal medical therapy, including oxygen supplementation, or surgical options, such as lung-volume reduction surgery for chronic obstructive pulmonary disease. Lung or lobar lung transplantation is an option for patients with end-stage lung disease despite these measures.

A lung transplant refers to single-lung or double-lung replacement. In a single-lung transplant, only one lung from a deceased donor is provided to the recipient. In a double-lung transplant, both the recipient's lungs are removed and replaced by the donor's lungs. In a lobar transplant, a lobe of the donor's lung is excised, sized appropriately for the recipient's thoracic dimensions, and transplanted. Donors for lobar transplant have primarily been living-related donors, with one lobe obtained from each of two donors (generally friends or family members) in cases for which bilateral transplantation is required. There are also cases of cadaver lobe transplants.

Since 2005, potential recipients have been ranked according to the Lung Allocation Score.¹ Patients 12 years of age and older receive a score between one and 100 based on predicted survival after transplantation reduced by predicted survival on the waiting list; the Lung Allocation Score takes into consideration the patient's disease and clinical parameters. In 2010, a simple priority system was implemented for children younger than age 12 years. Under this system, children younger than 12 years with respiratory lung failure and/or pulmonary hypertension who meet criteria are considered "priority 1" and all other candidates in the age group are considered "priority 2". A lung review board has the authority to adjust scores on appeal for adults and children.

Regulatory Status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation title 21, parts 1270 and 1271. Pancreas transplants are included in these regulations.

Related Protocols

Heart/Lung Transplant

Outpatient Pulmonary Rehabilitation

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Organ Procurement and Transplantation Network (OPTN). Organ Distribution: Allocation of Lungs. Policy 10. 2017; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed July 10, 2017.
2. Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016; 35(10):1170-1184. PMID 27772669
3. Goldfarb SB, Levvey BJ, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-Lung Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016; 35(10):1196-1205. PMID 27772671
4. Thabut G, Christie JD, Kremers WK, et al. Survival differences following lung transplantation among US transplant centers. *JAMA*. Jul 07 2010; 304(1):53-60. PMID 20606149
5. Black MC, Trivedi J, Schumer EM, et al. Double lung transplants have significantly improved survival compared with single lung transplants in high lung allocation score patients. *Ann Thorac Surg*. Nov 2014; 98(5):1737-1741. PMID 25110334
6. Yusen RD, Shearon TH, Qian Y, et al. Lung transplantation in the United States, 1999-2008. *Am J Transplant*. Apr 2010; 10(4 Pt 2):1047-1068. PMID 20420652
7. Shafii AE, Mason DP, Brown CR, et al. Too high for transplantation? Single-center analysis of the lung allocation score. *Ann Thorac Surg*. Nov 2014; 98(5):1730-1736. PMID 25218678
8. Date H. Update on living-donor lobar lung transplantation. *Curr Opin Organ Transplant*. Oct 2011; 16(5):453-457. PMID 21836512
9. Eberlein M, Reed RM, Chahla M, et al. Lobar lung transplantation from deceased donors: A systematic review. *World J Transplant*. Feb 24 2017; 7(1):70-80. PMID 28280698
10. Barr ML, Schenkel FA, Bowdish ME, et al. Living donor lobar lung transplantation: current status and future directions. *Transplant Proc*. Nov 2005; 37(9):3983-3986. PMID 16386604
11. Date H, Sato M, Aoyama A, et al. Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients. *Eur J Cardiothorac Surg*. Jun 2015; 47(6):967-972; discussion 972-963. PMID 25228745
12. Date H, Shiraishi T, Sugimoto S, et al. Outcome of living-donor lobar lung transplantation using a single donor. *J Thorac Cardiovasc Surg*. Sep 2012; 144(3):710-715. PMID 22717276
13. Slama A, Ghanim B, Klikovits T, et al. Lobar lung transplantation--is it comparable with standard lung transplantation? *Transpl Int*. Sep 2014; 27(9):909-916. PMID 24810771
14. Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report--2013; focus theme: age. *J Heart Lung Transplant*. Oct 2013; 32(10):965-978. PMID 24054805
15. Kilic A, Beaty CA, Merlo CA, et al. Functional status is highly predictive of outcomes after redo lung transplantation: an analysis of 390 cases in the modern era. *Ann Thorac Surg*. Nov 2013; 96(5):1804-1811. PMID 23968759
16. Kawut SM. Lung retransplantation. *Clin Chest Med*. Jun 2011; 32(2):367-377. PMID 21511096
17. Organ Procurement and Transplantation Network (OPTN). National Data. <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/>. Accessed July 12, 2017.
18. Ahmad U, Wang Z, Bryant AS, et al. Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry. *Ann Thorac Surg*. Sep 2012; 94(3):935-940; discussion 940-931. PMID 22835555
19. Organ Procurement and Transplantation Network (OPTN). Policy 15: Identification of Transmissible Diseases. 2017; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed July 10, 2017.
20. Bhagani S, Sweny P, Brook G, et al. Guidelines for kidney transplantation in patients with HIV disease. *HIV Med*. Apr 2006; 7(3):133-139. PMID 16494626
21. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with *Burkholderia cepacia* complex. *Am J Transplant*. May 2008; 8(5):1025-1030. PMID 18318775
22. Murray S, Charbeneau J, Marshall BC, et al. Impact of *Burkholderia* infection on lung transplantation in cystic fibrosis. *Am J Respir Crit Care Med*. Aug 15 2008; 178(4):363-371. PMID 18535253

23. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. *Thorax*. Aug 2008; 63(8):732-737. PMID 18408050
24. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. Jul 2006; 25(7):745-755. PMID 16818116
25. Medicare approved lung transplant centers. n.d.; <http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandCompliance/downloads/ApprovedTransplantPrograms.pdf>. Accessed July 10, 2017.